I-Mab Balance Sheet Health
Financial Health criteria checks 4/6
I-Mab has a total shareholder equity of CN¥1.7B and total debt of CN¥30.0M, which brings its debt-to-equity ratio to 1.7%. Its total assets and total liabilities are CN¥2.6B and CN¥894.8M respectively.
Key information
1.7%
Debt to equity ratio
CN¥29.97m
Debt
Interest coverage ratio | n/a |
Cash | CN¥2.28b |
Equity | CN¥1.72b |
Total liabilities | CN¥894.81m |
Total assets | CN¥2.61b |
Recent financial health updates
We're Keeping An Eye On I-Mab's (NASDAQ:IMAB) Cash Burn Rate
Feb 08Companies Like I-Mab (NASDAQ:IMAB) Are In A Position To Invest In Growth
May 24Recent updates
I-Mab: Trading Below Net Cash With Multiple Upside Options
Feb 18We're Keeping An Eye On I-Mab's (NASDAQ:IMAB) Cash Burn Rate
Feb 08I-Mab: Another CD47 Inhibitor Biotech With Great Potential
Sep 27I-Mab gets Chinese nod to start phase 3 combo treatment trial for myelodysplastic syndrome
Sep 13I-Mab Biopharma Non-GAAP EPADS of -$1.54, revenue of $7.74M
Aug 30I-Mab and senior executives may buy $40M worth of shares; stock up 10%
Aug 23Newsflash: I-Mab (NASDAQ:IMAB) Analysts Have Been Trimming Their Revenue Forecasts
Aug 20I-Mab doses first patient in phase 1 trial of TJ-CD4B in solid tumors in China
Jul 22I-Mab Valuation Offers A Biotech Investment Opportunity
Jun 23Companies Like I-Mab (NASDAQ:IMAB) Are In A Position To Invest In Growth
May 24I-Mab Shaken By Management Moves, Merger Talk And Delisting Threat
May 06Bearish: Analysts Just Cut Their I-Mab (NASDAQ:IMAB) Revenue and EPS estimates
Apr 01I-Mab Founder Retakes Reins In Latest Shakeup Ahead Of Commercialization Phase
Jan 03I-Mab Gets Boost From Latest Industry Signals On New Cancer Treatment
Oct 14Drug Maker I-Mab Wins Plaudits As Analysts Urge Caution On Soaring Stock
Jul 02I-Mab adds gastrointestinal oncology expert Andrew Zhu to Scientific Advisory Board
Jun 21I-Mab in talks seeking a billion-dollar deal for cancer therapy: Bloomberg
Jun 14Financial Position Analysis
Short Term Liabilities: IMAB's short term assets (CN¥2.3B) exceed its short term liabilities (CN¥411.8M).
Long Term Liabilities: IMAB's short term assets (CN¥2.3B) exceed its long term liabilities (CN¥483.0M).
Debt to Equity History and Analysis
Debt Level: IMAB has more cash than its total debt.
Reducing Debt: IMAB's debt to equity ratio has reduced from 7.5% to 1.7% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if IMAB has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if IMAB has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.